2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Sales - EUR | 180 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.028 | 0 |
Total Income - EUR | 3.393 | 6.130 | 4.495 | 0 | 0 | 0 | 0 | 0 | 2.028 | 0 |
Total Expenses - EUR | 5.024 | 2.271 | 3.191 | 3.855 | 572 | 0 | 0 | 263 | 1.926 | 6.832 |
Gross Profit/Loss - EUR | -1.631 | 3.859 | 1.304 | -3.855 | -572 | 0 | 0 | -263 | 101 | -6.832 |
Net Profit/Loss - EUR | -1.637 | 3.859 | 1.304 | -3.855 | -572 | 0 | 0 | -263 | 101 | -6.832 |
Employees | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 1 |
Check the financial reports for the company - Bioapicola S.r.l.
2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Fixed Assets | 87.718 | 86.179 | 83.052 | 79.437 | 77.980 | 76.469 | 0 | 77.298 | 76.483 | 75.200 |
Current Assets | 198.990 | 200.650 | 198.604 | 195.243 | 191.612 | 187.949 | 0 | 180.251 | 159.289 | 158.806 |
Inventories | 22.641 | 22.830 | 22.597 | 22.214 | 21.807 | 21.384 | 0 | 20.514 | 19.969 | 19.909 |
Receivables | 175.980 | 177.449 | 175.640 | 172.667 | 169.499 | 166.216 | 0 | 159.449 | 127.592 | 127.205 |
Cash | 368 | 371 | 368 | 361 | 306 | 348 | 0 | 288 | 11.727 | 11.691 |
Shareholders Funds | 34.447 | 38.594 | 39.504 | 34.980 | 33.766 | 33.673 | 0 | 41.002 | 41.495 | 34.537 |
Social Capital | 45 | 45 | 45 | 44 | 43 | 42 | 0 | 40 | 41 | 40 |
Debts | 207.252 | 208.982 | 242.152 | 205.924 | 202.669 | 198.230 | 0 | 194.857 | 172.521 | 177.778 |
Income in Advance | 45.008 | 39.254 | 34.358 | 33.776 | 33.157 | 32.514 | 0 | 21.690 | 21.757 | 21.691 |
Exchange rate - RON | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 | 4.4821 |
Main CAEN | "7022 - 7022" | |||||||||
CAEN Financial Year |
149
|
Subscriptions Financial Reports
You can check the financial situation of the companies in relation to the industry of which it is a part, credit limits and the risk of insolvency and suspension of accounts.
Comments - Bioapicola S.r.l.